ProMIS Neurosciences Completes Enrollment for Phase 1b Trial of PMN310 in Alzheimer’s Disease
I'm PortAI, I can summarize articles.
ProMIS Neurosciences Inc. has completed patient enrollment for its Phase 1b clinical trial of PMN310, a therapeutic antibody for Alzheimer's disease. The trial enrolled 144 patients, exceeding the initial target. It is a randomized, double-blind, placebo-controlled study to assess safety, tolerability, pharmacokinetics, biomarkers, and clinical effects of PMN310. Interim data is expected in Q2 2026, with final results in Q4 2026. No serious adverse events reported. Results pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments